Valuation of biomarkers.

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Valuation of biomarkers.

Abstract

References

Surrogate endpoints in clinical trials: definition and operational criteria

Surrogate end points in clinical trials: are we being misled?

The price of innovation: new estimates of drug development costs

Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development

The uses of biomarkers in drug development

How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Citations

Drug development for rare mitochondrial disorders

Mining biomarker information in biomedical literature

Aptamer based, non-PCR, non-serological detection of Chagas disease biomarkers in Trypanosoma cruzi infected mice

Imaging in the cardiovascular and metabolic disease area

Quality by design in lead optimization: a new strategy to address productivity in drug discovery

Maximizing the value of diagnostics in Alzheimer's disease drug development.

Translational precision medicine: an industry perspective.

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Related Papers

Biomarkers and surrogate markers: an FDA perspective

Disease-specific biomarker discovery by aptamers

Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease.

Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease.

Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray